Background
==========

Gastric cancer is a common and often fatal disease. Specifically, an estimated 951,000 cases of gastric cancer were newly diagnosed in 2012, leading to ranking this disease as the fifth most common type of cancer and third most common cause of cancer-related deaths worldwide.[@b1-ppa-12-909] Regarding the global burden of disease, 17.9 million disability-adjusted life-years (DALYs) worldwide were attributed to gastric cancer in 2013, which was identified as one of the top 3 causes of DALY among men.[@b2-ppa-12-909] Currently, Korea has the highest gastric cancer incidence in the world, with rates of 63.3 and 25.1 cases per 100,000 in male and female residents, respectively, and age-standardized mortality rates are 19.3 and 7.1 per 100,000 in male and female residents, respectively.[@b3-ppa-12-909]

The treatment of gastric cancer requires the use of modalities such as surgery, chemotherapy, and radiotherapy, which have been associated with high medical costs, several adverse effects, and low health-related quality of life (HRQOL).[@b4-ppa-12-909],[@b5-ppa-12-909] HRQOL can be measured using utility weights, which are scored from 1 for perfect health to 0 for death, and reflect an individual's preference for a specific health state.[@b6-ppa-12-909] The utility weight of a health state is a key component of quality-adjusted life year (QALY) calculations. In addition, the cost per QALY has been adopted by many countries as a critical and preferred value when conducting cost--utility analyses regarding decision-making for drug reimbursements and new health care interventions.[@b7-ppa-12-909]

Utility weights can be determined directly or indirectly. Direct methods incorporate valuation techniques such as the standard gamble (SG) and time trade-off (TTO), whereas indirect methods implement generic preference-based HRQOL instruments such as EQ-5D, SF-6D, or 15D, which use tariffs for utility-weight conversion. Although indirect methods are simpler and more time-efficient than direct methods, for hypothetical scenarios, the latter methods have the advantage of more abundantly reflecting disease-specific health states when compared with indirect methods that use generic preference-based HRQOL instruments with limited numbers of dimensions.

Utility weights can be determined from the perspectives of patients, health care professionals, or the general population.[@b8-ppa-12-909] Patients who have experienced a disease will best understand the disease-related health states but may assign relatively high utility weights because they have adapted to these health states.[@b9-ppa-12-909] Moreover, some researchers have opined that a utility-weight calculation from the perspective of the general population may be more valid in terms of economic views on the allocation of limited resources.[@b10-ppa-12-909] However, recent systematic reviews addressing studies of the utilities of gastric cancer-associated health states reported the nonexistence of utility-weight data derived from general populations.[@b11-ppa-12-909],[@b12-ppa-12-909]

Although many studies have measured the utility weights of gastric cancer-related health states, these studies were restricted to health states associated with particular stages of gastric cancer and to the viewpoint of gastric cancer patients.[@b13-ppa-12-909] The present study aimed to determine the utility weights of gastric cancer-related health states across a wide range of stages and treatment strategies from the perspective of the general population, using SG.

Methods
=======

Study sample
------------

Adults aged ≥19 years were sampled using a multistage stratified quota sampling method. The sample quota was assigned to 15 districts in Korea. At this time, the allocation criteria were the population numbers of the 15 districts and sociodemographic factors of gender, age, and education level according to the population structure to represent the general Korean population.

Gastric cancer-related hypothetical health states
-------------------------------------------------

To include the entire progression of gastric cancer, we created 9 descriptions of gastric cancer-related hypothetical health states using a uniform format that included diagnosis, symptoms, treatment, and disease prognosis with 5-year survival rates. These states included 1) no gastric cancer with *Helicobacter pylori* infection (NG with HP), 2) early gastric cancer (EGC) with endoscopic surgery (EGC with ES), 3) EGC with subtotal gastrectomy (EGC with STG), 4) EGC with total gastrectomy (EGC with TG), 5) advanced gastric cancer (AGC) with subtotal gastrectomy and adjuvant chemotherapy (AGC with STG/Chemo), 6) AGC with total gastrectomy and adjuvant chemotherapy (AGC with TG/Chemo), 7) AGC with extended gastrectomy and adjuvant chemotherapy (AGC with EG/Chemo), 8) metastatic gastric cancer with palliative chemotherapy (MGC with Chemo), and 9) recurrent gastric cancer with palliative chemotherapy (RGC with Chemo). The descriptions of the health scenarios included sufficient information that was provided in simple language and based on the cancer information service of the National Cancer Information Center,[@b14-ppa-12-909] Korean clinical practice guideline for gastric cancer,[@b15-ppa-12-909] and patient education materials to allow the respondents to imagine the hypothetical health scenarios.

Survey
------

The survey was conducted from August to October 2014 by trained interviewers using a computer-assisted personal interviewing method. We trained interviewers about the meaning of 9 health states and how to conduct SG. After training, we took pairs of interviewers and let them practice interviewing each other. Total training time was about 2.5 h. The respondents were asked to perform SG tasks for 5 health states randomly selected from among the 9 devised states. After completing the SG tasks, the respondents were asked questions to solicit background information such as sex, age, education period, household income, and health care utilization (including ambulatory medical visits and hospitalization). After completion of the survey, respondents randomly selected by sex and age were asked by telephone about their sex, age, and participation in this survey. This survey was approved by the Institutional Review Board of Asan Medical Center Seoul, Korea (Approval number S2014-1396-000), and written informed consent was obtained from all participants prior to enrollment.

Utility-weight measurement methods
----------------------------------

A SG method, which is regarded as the gold standard for eliciting utility weights, was used to measure the utility weights of the health states.[@b16-ppa-12-909] Before beginning SG, the respondents were asked if the health states were better or worse than death. Subsequently, for the SG process, the respondents were asked to choose 1 of 2 alternatives. In this study, one alternative was to live in 1 of 9 health states with certainty for 10 years, and the other was to accept a treatment with 2 possible but uncertain outcomes: perfect health with a probability *p* vs immediate death with a probability 1−*p*. A moderate probability *p* (ie, 0.5) was offered for the perfect health state at the beginning of each SG task and the probability value *p* was changed until the respondents expressed indifference between the 2 alternatives. At that point, the utility weight for the state was defined as the *p*-value.

Criteria for the exclusion of data from the analysis
----------------------------------------------------

Logical criteria were used to exclude respondents from the analysis. Data were excluded if the respondents did not correctly understand the meanings of SG tasks and the resulting data might be interpreted as invalid. In addition, respondents who assigned the same value to all states or valued all states as worse than death were excluded from the analysis.[@b17-ppa-12-909] Logical inconsistency was also used as an exclusion criterion. In this study, scenarios were developed according to gastric cancer progression and can be categorized as follows: 1) cancer-free state (NG with HP), 2) EGC states (EGC with ES, STG, or TG), 3) AGC states (AGC with STG/Chemo, TG/Chemo, or EG/Chemo), and 4) metastatic or RGC states (MGC with Chemo or RGC with Chemo). Therefore, in a pair of health states from different categories, a better state would be expected to receive the same or a higher score relative to the other and this pair would be considered logically consistent. Based on this criterion, respondents for whom we found more than 3 logically inconsistent pairs of health states were excluded from the analysis.[@b18-ppa-12-909]

Data analysis
-------------

The respondents' characteristics were summarized using descriptive statistics. The utility weights derived using the SG method were calculated as follows: the probability *p* at the point of indifference was set as the utility weight for each state if the respondent answered that the state was better than death. In the opposite case (ie, the respondent answered that the state was worse than death), the utility weight for the state was censored at zero. The mean utility weights of the 9 health states were subjected to an analysis of variance (ANOVA) to assess differences, and a Dunnett T3 post hoc analysis was used to compare one mean utility weight with the other. The independent two-sample *t*-test and ANOVA were used to evaluate mean differences according to respondents' characteristics. A multivariate regression was performed to identify relationships among the respondents' characteristics as independent variables, using the utility weights as the dependent variable. All statistical analyses were conducted using STATA 13 (StataCorp, College Station, TX, USA).

Results
=======

A total of 407 adults completed this survey. Of these, 81 respondents were excluded: 16 assigned the same utility weight to all states and 65 had more than 3 inconsistencies. A frequency distribution of the logical inconsistencies is shown in [Table S1](#SD1-ppa-12-909){ref-type="supplementary-material"}. Subsequently, 326 respondents were included in the study analysis. The respondents had an average age of 45 years (range: 19--80 years), and half of them were female. The majority of respondents had no experience with ambulatory care visits during the past 2 weeks (89.3%) or hospital admission within the past 1 year (96.0%), or no morbidity (86.8%; [Table 1](#t1-ppa-12-909){ref-type="table"}).

The mean utility weights of the gastric cancer-related health states are listed in [Table 2](#t2-ppa-12-909){ref-type="table"}. The mean utility weights tended to decrease according to gastric cancer progression from NG with HP to RGC with Chemo. The respondents presented similar utility weights for the same stages, regardless of treatment: the utility weights of EGC with ES, EGC with STG, and EGC with TG were 0.773, 0.779, and 0.767, respectively, and those for AGC with STG/Chemo and AGC with TG/Chemo were 0.602 and 0.643, respectively. The respondents also reported similar preferences regarding the scenarios of MGC with Chemo and RGC with Chemo (0.404 and 0.399, respectively).

The utility weights differed statistically across the 9 health states (*F*=73.171, *p*\<0.001). A Dunnett T3 analysis found no statistical differences between NG with HP and EGC with STG; among EGC with ES, EGC with STG, and EGC with TG; between AGC with STG/Chemo and AGC with TG/Chemo; and between MGC with Chemo and RGC with Chemo ([Table S2](#SD2-ppa-12-909){ref-type="supplementary-material"}). Moreover, no statistically significant differences in the mean utility weights were observed according to the respondents' characteristics such as gender, household monthly income, ambulatory care visit in the past 2 weeks, and morbidity ([Table 3](#t3-ppa-12-909){ref-type="table"}).

The multivariate regression identified 4 variables that were significantly related to the utility weights: age, household monthly income, ambulatory care visit in the past 2 weeks, and hospitalization in the past year. Respondents gave higher utility weights if they were aged 30--39 or \>60 years, if their household monthly income was above the median, if they had used ambulatory care in the past 2 weeks, or if they had not been hospitalized during the past year ([Table 4](#t4-ppa-12-909){ref-type="table"}).

Discussion
==========

In the current study, respondents from the general population assigned utility weights to gastric cancer-related health states using a SG method. The respondents assigned the highest utility weight to NP with HP and the lowest to RGC with Chemo. The respondents gave lower utility weights to worse stages of gastric cancer.

Interestingly, the utility weights assigned by the general population to scenarios within the same gastric cancer stage did not differ significantly with respect to the treatment method. This suggests that the general population is more affected by the gastric cancer stage than by the treatment method when valuing gastric cancer-related health states. Previous studies of HRQOL of patients who had received STG or TG reported no significant difference between these treatments, and a systematic review of HRQOL after gastrectomy for gastric cancer showed that most studies found no statistically significant difference between STG and TG.[@b12-ppa-12-909] Bae et al reported that among disease-free gastric cancer survivors, HRQOL did not differ significantly between those who received STG and TG.[@b19-ppa-12-909]

The respondents in this study assigned a mean utility weight of 0.857 to NG with HP. Although this value was the highest among the 9 states, it was relatively low for an absence of gastric cancer. Korea has some of the highest prevalence rates of *H. pylori* infection and gastric cancer worldwide.[@b20-ppa-12-909] In addition, a Korean general population-based study reported awareness of *H. pylori* as a risk factor for gastric cancer.[@b21-ppa-12-909] This awareness might have affected the valuation for the health state of NG with HP.

Because this study, to the best of our knowledge, was the first to examine the utility weights of gastric cancer-related health states in a general population, we cannot directly compare the results to those of previous studies. However, the utility weights obtained from a general population in the current study were generally lower than those obtained in previous studies of gastric cancer patients. In several studies, patients who underwent surgery for gastric cancer reported utility weights of 0.77[@b13-ppa-12-909] and 0.80[@b22-ppa-12-909] with EQ-5D and 0.85[@b23-ppa-12-909] with TTO. Moreover, a utility weight of 0.83 was reported for patients undergoing chemo/radiotherapy,[@b13-ppa-12-909] and a study of patients who had attended 2--4 chemotherapy sessions, conducted at ≥20 days after the last session, reported utility weights of 0.55 for EQ-5D, 0.61 for SF-6D, and 0.69 for 15D.[@b24-ppa-12-909] In the current study, the general population assigned utility weights of 0.767--0.779 for EGC with STG or TG and 0.522--0.643 for AGC with STG/Chemo, TG/Chemo, or EG/Chemo; these were relatively lower than those assigned by patients. Regarding MGC or RGC, patients with advanced adenocarcinoma of the stomach or esophagogastric junction in the recurrent or metastatic state assigned weights of 0.66--0.76 when using EQ-5D.[@b25-ppa-12-909] These were much higher than the utility weights of 0.399--0.404 assigned to MGC or RGC with Chemo by participants in the current study. However, another earlier TTO-based study reported that patients with MGC assigned a utility weight of 0.35, which was lower than the value assigned in the present study.[@b23-ppa-12-909]

The lower utility weights in this study relative to those in previous studies can be attributed to several factors. First, all previous studies of the utility weights of gastric cancer states were conducted from the patient's perspective. Patients might have not responded to and consequently been excluded from studies because of a poor health state, and patients who had adjusted well to gastric cancer were likely to be selected for study participation.[@b12-ppa-12-909] Therefore, when using utility weights of a health state, one must consider whether the values were derived from patients or from the community. Second, the general population might have assigned low utility weights because the health state scenarios used in this study included information about postoperative symptoms or possible complications. Third, the choice of valuation method might have had an effect. Most previous studies of gastric cancer-related utility weights were conducted using an indirect EQ-5D-based method. The EQ-5D, which consists of 5 dimensions, was reported to show a high ceiling effect, and to be insensitive to patients' health changes.[@b26-ppa-12-909] Generic tools used to measure utility weights (including EQ-5D) might be less sensitive to changes in a patient's health state than disease-specific instruments.[@b27-ppa-12-909] Accordingly, the utility weights obtained using generic tools might be higher than those assigned in the present study.

The multivariate regression in this study identified age, household income, and experiences with ambulatory care visits or hospitalization as factors that significantly influenced a respondent's valuation of health states. Other reports have indicated that sociodemographic characteristics such as age, income, and education may affect a respondent's utility weights.[@b28-ppa-12-909],[@b29-ppa-12-909] The finding that several sociodemographic variables affected the valuation results in the present study suggests the importance of representative sampling when valuing various health states.

The current study had some limitations. First, although the respondents were generally similar to the general population of the 2010 population census in terms of sex, age, and education period, the current study respondents included fewer participants aged 19--39 years and more respondents aged \>40 years when compared with the general population. In addition, the proportions of participants aged \>70 years differed with rates of 2.1% in the current study and 9.6% in the general population. Accordingly, the perspective of people aged \>70 years might have been disproportionately less reflected in the utility weights from this study. Furthermore, respondents in the current study were much less likely to have used ambulatory care in the past 2 weeks or to have been hospitalized in the past year, compared with participants in the nationwide 2014 Korea National Health and Nutrition Examination Survey; in other words, the study sample was likely healthier than the general population. To evaluate selection bias, we compared the utilities for each health state between participants who have used ambulatory care or been hospitalized in the past and those who have not, and most of the differences were not statistically significant. Second, interviews with gastric cancer patients were not included in scenario development. Each health state description was formatted uniformly, according to clinical guidelines and health education materials, to ensure that respondents were provided structured and sufficient information about gastric cancer-related health states. The scenarios were developed to investigate how respondents would evaluate gastric cancer-related health states when given sufficient information about the diagnosis, symptoms, treatment, and prognosis. Information provided by patients who have experienced gastric cancer and/or postoperative states would help to enrich and verify the scenarios. Third, this study has limitations to its generalization. Although this study attempted to include various gastric cancer-related health states and was conducted in a representative Korean population, the results should be applied cautiously. The hypothetical health states were subdivided according to stage, but even in the same stage, there may be variations in the corresponding health state. In addition, this study was aimed at the general population in Korea, so there are limitations to generalizability because there are reports that utilities vary according to culture or health care delivery systems.[@b30-ppa-12-909],[@b31-ppa-12-909] This means that utilities derived from other countries must be used cautiously.

Despite these limitations, the results of this study can be useful for economic evaluation of screening and treatment in gastric cancer. The many studies that performed economic evaluations of screening tests, surgery, or chemotherapy for gastric cancer have used utilities for gastric cancer-related health states.[@b32-ppa-12-909]--[@b34-ppa-12-909] Given that gastric cancer has a relatively high prevalence and incidence in Asians, these results might be considered if there is a paucity of research on utilities of gastric cancer-related health states in Asia.[@b35-ppa-12-909]

Conclusion
==========

Our study provided utility weights for a wide range of gastric cancer-related states from the perspective of a general population using direct valuation method with SG. In the future, the utility weights derived from this study will be useful for gastric cancer-related economic evaluations.

Supplementary materials
=======================

###### 

Frequency distribution of logical inconsistencies

  No of logical inconsistencies   N     \%
  ------------------------------- ----- -------
  0                               235   60.1
  1                               34    8.7
  2                               30    7.7
  3                               27    6.9
  4                               22    5.6
  5                               15    3.8
  6                               10    2.6
  7                               12    3.1
  8                               5     1.3
  9                               1     0.3
  Total                           391   100.0

**Note:** Frequency distribution of logical inconsistencies (N=391).

###### 

Comparison of the mean utility weights between health states using a Dunnett T3 post hoc analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Gastric cancer-related health states   Mean difference\                                    Standard error                                      
                                         (I--J)                                                                                                  
  -------------------------------------- --------------------------------------------------- --------------------------------------------------- -------
  NG with HP                             EGC with ES                                         0.084[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.026

  EGC with STG                           0.078                                               0.025                                               

  EGC with TG                            0.090[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.025                                               

  AGC with STG/Chemo                     0.255[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.026                                               

  AGC with TG/Chemo                      0.214[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.025                                               

  AGC with EG/Chemo                      0.335[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.025                                               

  MGC with Chemo                         0.453[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.028                                               

  RGC with Chemo                         0.458[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.026                                               

  EGC with ES                            NG with HP                                          −0.084[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.026

  EGC with STG                           −0.006                                              0.028                                               

  EGC with TG                            0.006                                               0.028                                               

  AGC with STG/Chemo                     0.171[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.029                                               

  AGC with TG/Chemo                      0.130[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.028                                               

  AGC with EG/Chemo                      0.252[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.028                                               

  MGC with Chemo                         0.369[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.030                                               

  RGC with Chemo                         0.375[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.029                                               

  EGC with STG                           NG with HP                                          −0.078                                              0.025

  EGC with ES                            0.006                                               0.028                                               

  EGC with TG                            0.011                                               0.028                                               

  AGC with STG/Chemo                     0.177[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.028                                               

  AGC with TG/Chemo                      0.136[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.028                                               

  AGC with EG/Chemo                      0.257[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.028                                               

  MGC with Chemo                         0.375[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.030                                               

  RGC with Chemo                         0.380[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.029                                               

  EGC with TG                            NG with HP                                          −0.090[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.025

  EGC with ES                            −0.006                                              0.028                                               

  EGC with STG                           −0.011                                              0.028                                               

  AGC with STG/Chemo                     0.165[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.028                                               

  AGC with TG/Chemo                      0.125[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.027                                               

  AGC with EG/Chemo                      0.246[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.027                                               

  MGC with Chemo                         0.364[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.030                                               

  RGC with Chemo                         0.369[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.029                                               

  AGC with STG/Chemo                     NG with HP                                          −0.255[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.026

  EGC with ES                            −0.171[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.029                                               

  EGC with STG                           −0.177[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.028                                               

  EGC with TG                            −0.165[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.028                                               

  AGC with TG/Chemo                      −0.041                                              0.028                                               

  AGC with EG/Chemo                      0.080                                               0.028                                               

  MGC with Chemo                         0.198[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.030                                               

  RGC with Chemo                         0.204[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.029                                               

  AGC with TG/Chemo                      NG with HP                                          −0.214[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.025

  EGC with ES                            −0.130[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.028                                               

  EGC with STG                           −0.136[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.028                                               

  EGC with TG                            −0.125[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.027                                               

  AGC with STG/Chemo                     0.041                                               0.028                                               

  AGC with EG/Chemo                      0.121[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.027                                               

  MGC with Chemo                         0.239[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.030                                               

  RGC with Chemo                         0.244[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.029                                               

  AGC with EG/Chemo                      NG with HP                                          −0.335[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.025

  EGC with ES                            −0.252[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.028                                               

  EGC with STG                           −0.257[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.028                                               

  EGC with TG                            −0.246[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.027                                               

  AGC with STG/Chemo                     −0.080                                              0.028                                               

  AGC with TG/Chemo                      −0.121[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.027                                               

  MGC with Chemo                         0.118[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.030                                               

  RGC with Chemo                         0.123[\*](#tfn8-ppa-12-909){ref-type="table-fn"}    0.029                                               

  MGC with Chemo                         NG with HP                                          −0.453[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.028

  EGC with ES                            −0.369[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.030                                               

  EGC with STG                           −0.375[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.030                                               

  EGC with TG                            −0.364[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.030                                               

  AGC with STG/Chemo                     −0.198[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.030                                               

  AGC with TG/Chemo                      −0.239[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.030                                               

  AGC with EG/Chemo                      −0.118[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.030                                               

  RGC with Chemo                         0.005                                               0.031                                               

  RGC with Chemo                         NG with HP                                          −0.458[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.026

  EGC with ES                            −0.375[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.029                                               

  EGC with STG                           −0.380[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.029                                               

  EGC with TG                            −0.369[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.029                                               

  AGC with STG/Chemo                     −0.204[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.029                                               

  AGC with TG/Chemo                      −0.244[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.029                                               

  AGC with EG/Chemo                      −0.123[\*](#tfn8-ppa-12-909){ref-type="table-fn"}   0.029                                               

  MGC with Chemo                         −0.005                                              0.031                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

*p*-value \<0.05.

**Abbreviations:** AGC with EG/Chemo, advanced gastric cancer with extended gastrectomy with adjuvant chemotherapy; AGC with STG/Chemo, advanced gastric cancer with subtotal gastrectomy and adjuvant chemotherapy; AGC with TG/Chemo, advanced gastric cancer with total gastrectomy and adjuvant chemotherapy; EGC with ES, early gastric cancer with endoscopic surgery; EGC with STG, early gastric cancer with subtotal gastrectomy; EGC with TG, early gastric cancer with total gastrectomy; MGC with Chemo, metastatic gastric cancer with palliative chemotherapy; NG with HP, no gastric cancer with *Helicobacter pylori* infection; RGC with Chemo, recurrent gastric cancer with palliative chemotherapy.
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###### 

Sociodemographic characteristics of respondents (N=326)

                                                        Study sample   General population[a](#tfn1-ppa-12-909){ref-type="table-fn"}   
  ----------------------------------------------------- -------------- -------------------------------------------------------------- ------
  Gender                                                                                                                              
   Female                                               163            50.0                                                           51.0
   Male                                                 163            50.0                                                           49.0
  Age, years                                                                                                                          
   Mean (SD)                                            45.1 (14.1)                                                                   
   19--29                                               55             16.9                                                           19.4
   30--39                                               66             20.2                                                           20.8
   40--49                                               72             22.1                                                           21.9
   50--59                                               60             18.4                                                           17.5
   60 or more                                           73             22.4                                                           20.3
  Education period, years                                                                                                             
   High school or below (≤12)                           179            54.9                                                           56.2
   College or above (\>12)                              147            45.1                                                           43.8
  Household monthly income, USD                                                                                                       
   First quartile (≤2,400)                              80             24.5                                                           
   Second quartile (2,400--3,000)                       81             24.8                                                           
   Third quartile (3,000--4,300)                        83             25.5                                                           
   Fourth quartile (\>4,300)                            82             25.2                                                           
  Ambulatory care visit in past 2 weeks                                                                                               
   Yes                                                  35             10.7                                                           35.1
   No                                                   291            89.3                                                           64.9
  Hospitalization in the past year                                                                                                    
   Yes                                                  13             4.0                                                            11.1
   No                                                   313            96.0                                                           88.9
  Morbidity[b](#tfn2-ppa-12-909){ref-type="table-fn"}                                                                                 
   Yes                                                  43             13.2                                                           
   No                                                   283            86.8                                                           

**Notes:**

The gender, age, and education period of the general population were obtained from the 2010 population census, and ambulatory care visit and hospitalization data for the general population were obtained from the 2014 Korea National Health and Nutrition Examination Survey.

Defined as the presence of any disease in the respondents. Out of 43 with diseases, 21 (49%) had hypertension, 12 (28%) diabetes mellitus, 8 (19%) musculoskeletal disorders, and 4 (9%) hyperlipidemia.

###### 

Utility weights of gastric cancer-related health states derived using a standard gamble method

                       Observation number   Mean    SD      Median   IQR
  -------------------- -------------------- ------- ------- -------- -------
  NG with HP           188                  0.857   0.218   0.950    0.150
  EGC with ES          184                  0.773   0.274   0.900    0.250
  EGC with STG         164                  0.779   0.254   0.900    0.250
  EGC with TG          185                  0.767   0.263   0.900    0.250
  AGC with STG/Chemo   175                  0.602   0.270   0.650    0.400
  AGC with TG/Chemo    191                  0.643   0.264   0.700    0.350
  AGC with EG/Chemo    183                  0.522   0.265   0.600    0.400
  MGC with Chemo       166                  0.404   0.292   0.375    0.480
  RGC with Chemo       194                  0.399   0.295   0.400    0.500

**Abbreviations:** AGC with EG/Chemo, advanced gastric cancer with extended gastrectomy and adjuvant chemotherapy; AGC with STG/Chemo, advanced gastric cancer with subtotal gastrectomy and adjuvant chemotherapy; AGC with TG/Chemo, advanced gastric cancer with total gastrectomy and adjuvant chemotherapy; EGC with ES, early gastric cancer with endoscopic surgery; EGC with STG, early gastric cancer with subtotal gastrectomy; EGC with TG, early gastric cancer with total gastrectomy; MGC with Chemo, metastatic gastric cancer with palliative chemotherapy; IQR, interquartile range; NG with HP, no gastric cancer with *Helicobacter pylori* infection; RGC with Chemo, recurrent gastric cancer with palliative chemotherapy.

###### 

Mean utility weights for gastric cancer-related health states according to respondents' characteristics

  Mean (SD)                               NG with HP   EGC with ES   EGC with STG                                       EGC with TG   AGC with STG/Chemo                                 AGC with TG/Chemo                                    AGC with EG/Chemo   MGC with Chemo                                     RGC with Chemo
  --------------------------------------- ------------ ------------- -------------------------------------------------- ------------- -------------------------------------------------- ---------------------------------------------------- ------------------- -------------------------------------------------- ----------------
  Gender                                                                                                                                                                                                                                                                                                             
   Male                                   0.869        0.785         0.792                                              0.788         0.596                                              0.653                                                0.526               0.391                                              0.402
   Female                                 0.841        0.760         0.768                                              0.746         0.607                                              0.633                                                0.517               0.416                                              0.395
  Age, years                                                                                                                                                                                                                                                                                                         
   19--29                                 0.848        0.759         0.694                                              0.816         0.545                                              0.581                                                0.469               0.338[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.338
   30--39                                 0.874        0.829         0.759                                              0.793         0.594                                              0.702                                                0.577               0.466[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.444
   40--49                                 0.909        0.682         0.791                                              0.760         0.606                                              0.634                                                0.493               0.336[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.328
   50--59                                 0.856        0.779         0.803                                              0.779         0.621                                              0.631                                                0.527               0.335[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.417
   60 or more                             0.782        0.806         0.837                                              0.703         0.632                                              0.648                                                0.536               0.496[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.440
  Education period, years                                                                                                                                                                                                                                                                                            
   ≤12                                    0.845        0.774         0.822[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.766         0.612                                              0.643                                                0.534               0.433                                              0.400
   \>12                                   0.869        0.773         0.729[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.769         0.588                                              0.643                                                0.505               0.363                                              0.397
  Household monthly income                                                                                                                                                                                                                                                                                           
   First quartile                         0.808        0.763         0.790                                              0.717         0.567                                              0.584                                                0.486               0.401                                              0.373
   Second quartile                        0.866        0.741         0.794                                              0.766         0.585                                              0.621                                                0.462               0.421                                              0.346
   Third quartile                         0.858        0.815         0.767                                              0.767         0.634                                              0.686                                                0.554               0.413                                              0.408
   Fourth quartile                        0.890        0.778         0.763                                              0.814         0.624                                              0.686                                                0.584               0.380                                              0.469
  Ambulatory care visit in past 2 weeks                                                                                                                                                                                                                                                                              
   Yes                                    0.878        0.814         0.817                                              0.785         0.642                                              0.575                                                0.590               0.450                                              0.418
   No                                     0.855        0.769         0.774                                              0.765         0.597                                              0.649                                                0.514               0.397                                              0.396
  Hospitalization in past 1 year                                                                                                                                                                                                                                                                                     
   Yes                                    0.750        0.706         0.733                                              0.675         0.406[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.350[\*\*](#tfn5-ppa-12-909){ref-type="table-fn"}   0.450               0.395                                              0.317
   No                                     0.860        0.777         0.780                                              0.770         0.611[\*](#tfn4-ppa-12-909){ref-type="table-fn"}   0.654[\*\*](#tfn5-ppa-12-909){ref-type="table-fn"}   0.524               0.404                                              0.402
  Morbidity                                                                                                                                                                                                                                                                                                          
   Yes                                    0.850        0.739         0.844                                              0.729         0.606                                              0.669                                                0.519               0.428                                              0.383
   No                                     0.858        0.777         0.771                                              0.774         0.601                                              0.639                                                0.522               0.400                                              0.401

**Notes:**

*p*-value \<0.05;

*p*-value \<0.01.

**Abbreviations:** AGC with EG/Chemo, advanced gastric cancer with extended gastrectomy with adjuvant chemotherapy; AGC with STG/Chemo, advanced gastric cancer with subtotal gastrectomy and adjuvant chemotherapy; AGC with TG/Chemo, advanced gastric cancer with total gastrectomy and adjuvant chemotherapy; EGC with ES, early gastric cancer with endoscopic surgery; EGC with STG, early gastric cancer with subtotal gastrectomy; EGC with TG, early gastric cancer with total gastrectomy; MGC with Chemo, metastatic gastric cancer with palliative chemotherapy; NG with HP, no gastric cancer with *Helicobacter pylori* infection; RGC with Chemo, recurrent gastric cancer with palliative chemotherapy.

###### 

Multivariate regression analysis of utility weights according to respondents' characteristics

                                          Coefficients   Standard errors   *t*     *p*-value
  --------------------------------------- -------------- ----------------- ------- -----------
  Gender                                                                           
   Male                                   Reference                                
   Female                                 −0.014         0.015             −0.89   0.373
  Age, years                                                                       
   19--29                                 Reference                                
   30--39                                 0.088          0.025             3.47    0.001
   40--49                                 0.024          0.025             0.94    0.347
   50--59                                 0.050          0.027             1.84    0.066
   60 or more                             0.074          0.031             2.40    0.017
  Education period, years                                                          
   ≤12                                    Reference                                
   \>12                                   −0.023         0.018             −1.28   0.199
  Household monthly income                                                         
   First quartile                         Reference                                
   Second quartile                        0.040          0.024             1.67    0.095
   Third quartile                         0.071          0.024             2.89    0.004
   Fourth quartile                        0.104          0.025             4.15    \<0.001
  Ambulatory care visit in past 2 weeks                                            
   Yes                                    Reference                                
   No                                     −0.075         0.029             −2.57   0.010
  Hospitalization in past 1 year                                                   
   Yes                                    Reference                                
   No                                     0.165          0.041             4.04    \<0.001
  Morbidity                                                                        
   Yes                                    Reference                                
   No                                     0.025          0.026             0.94    0.347
  Constant                                0.440          0.056             7.89    \<0.001
